Tags : BioXcel Therapeutics


Bioxcel, Nektar and Merck KGaA in a Triple Collaboration for

Shots: The companies entered into a clinical collaboration for evaluating BioXcel’s BXCL701, Nektar’s NKTR-214 & Avelumab (co-developed and co-commercialized by Merck KGaA and Pfizer) as a triple combination therapy for pancreatic cancer In Nov,2017, BTI and Nektar Therapeutics initially collaborated for preclinical development and expand their collaboration on 24 Sept,2018 for novel triple combination therapy […]Read More